MONOPAR and NORTHSTAR Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility toward Human Trials.
Monopar
Therapeutics Inc. and NorthStar Medical Radioisotopes, LLC announced an
expansion of their radiopharmaceutical collaboration along with a new
radiolabeled imaging candidate designated as MNPR-101-Zr, an antibody against
urokinase plasminogen activator receptor. Based on promising recently-generated
preclinical imaging results with MNPR-101-Zr showing a high uptake across
multiple tumor types, the companies committed to additional funding with the
aim of initiating a first-in-human imaging study with MNPR-101-Zr as early as
the end of this year.
To read more please visit:
Source: NORTHSTAR